{
  "id": 26042,
  "title": "Twice-Rejected Melanoma Drug Gets Love From FDA Panel",
  "url": "https://urgent.news/2026/07/30/twice-rejected-melanoma-drug-gets-love-from-fda-panel",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-07-30T22:28:09.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/hematologyoncology/skincancer/122431"
  },
  "original_language": "en",
  "account": "The FDA advisory committee has given a vote of confidence to RP1, a melanoma drug candidate that has been rejected twice by the agency. Despite skepticism from reviewers, the Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 in favor of the phase II IGNYTE study, which tested RP1 combined with nivolumab. The study showed promising results, with 33.6% of patients responding to the treatment, including complete responses in 16.4%. The drugmaker, Replimune, is seeking accelerated approval based on these findings, which were gathered from patients with advanced melanoma who had already progressed on anti-PD-1 therapy.",
  "summary": "(MedPage Today) -- In the wake of a surprise FDA advisory committee vote on Thursday, the third time could be the charm for RP1 (vusolimogene oderparepvec), a melanoma drug candidate that's already been rejected twice by the agency. Despite doubts...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}